Related Experiment Video
Updated: Feb 1, 2026
09:22
Appetitive Associative Olfactory Learning in Drosophila Larvae
Published on: February 18, 2013
19.7K
The Chimera That Curbs Appetite
1Departments of Chemistry, Oncology, and Medical Imaging , University of Western Ontario , London , ON N6A 4L6 , Canada.
Journal of Medicinal Chemistry
|December 4, 2018
Summary
Researchers developed a novel chimeric drug design by combining antagonist and inverse agonist structures. This approach yields a new molecular scaffold for targeting the ghrelin receptor (GHSR).
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- The ghrelin receptor (GHSR) is a key target for metabolic and endocrine disorders.
- Existing ghrelin receptor modulators have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To design and characterize a novel molecular scaffold for ghrelin receptor (GHSR) targeting.
- To explore a chimeric drug design strategy combining antagonist and inverse agonist properties.
Main Methods:
- Utilized a chimeric drug design approach.
- Merged structural features of known ghrelin receptor antagonists and inverse agonists.
- Synthesized and characterized the resulting novel molecular scaffold.
Main Results:
- Successfully generated a new molecular scaffold with potential for GHSR modulation.
- The chimeric design integrates key pharmacophoric elements from both antagonist and inverse agonist classes.
Conclusions:
- The developed chimeric scaffold represents a promising new avenue for ghrelin receptor (GHSR) targeted drug development.
- This approach offers a versatile platform for creating novel modulators with potentially unique pharmacological profiles.
